A Comprehensive Report on 68Ga-PSFA: A Novel Bispecific Radiotracer for Prostate Cancer Theranostics

Executive Summary

This report provides an expert-level analysis of 68Ga-PSFA, a novel bispecific positron emission tomography (PET) radiotracer targeting both Prostate-Specific Membrane Antigen (PSMA) and Fibroblast Activation Protein (FAP). It addresses the significant clinical challenge of tumor heterogeneity in prostate cancer, which leads to PSMA-negative or low-expressing lesions, thereby limiting the efficacy of current PSMA-targeted diagnostics and therapies. The report synthesizes the molecular characteristics, preclinical data, and emerging clinical evidence for 68Ga-PSFA, contextualizing its development within the broader landscape of prostate cancer imaging. Key findings indicate that by targeting both the cancer cell (via PSMA) and the tumor stroma (via FAP), 68Ga-PSFA has the potential to provide more comprehensive disease staging, improve patient selection for targeted therapies, and serve as a diagnostic forerunner to bispecific radioligand therapies. The analysis concludes with a forward-looking assessment of its theranostic implications, clinical development pathway, and the challenges to its widespread adoption, including interpretation standardization and reimbursement.

I. The Evolving Landscape of Prostate Cancer Molecular Imaging

The management of prostate cancer has been fundamentally transformed by the advent of molecular imaging agents that can visualize disease with unprecedented accuracy. This section establishes the clinical and scientific foundation for this revolution, detailing the rise of 68Ga-PSMA-11 as the standard of care and critically evaluating its performance and limitations, thereby creating the rationale for developing next-generation agents like 68Ga-PSFA.

Section 1.1: Prostate-Specific Membrane Antigen (PSMA) as a Foundational Biomarker

The clinical utility of modern prostate cancer imaging is built upon the biological characteristics of Prostate-Specific Membrane Antigen (PSMA), a cell surface protein that has proven to be an exceptional theranostic target.

PSMA Biology and Expression

PSMA is a type II transmembrane glycoprotein encoded by the Folate Hydrolase 1 (FOLH1) gene.[1] While expressed at low levels in several normal tissues, including the kidneys, salivary glands, and small intestine, its clinical relevance is derived from its dramatic overexpression in malignant prostate tissue.[2] More than 90% of prostate adenocarcinomas exhibit PSMA levels that are 100- to 1,000-fold higher than in benign prostate cells.[4] This high expression correlates with tumor aggressiveness, higher Gleason scores, advanced disease stage, and the development of metastatic castration-resistant prostate cancer (mCRPC), making PSMA an ideal target for both diagnostic imaging and targeted therapy.[5]

Enzymatic Function

PSMA possesses dual enzymatic activities as both a folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase).[1] This enzymatic function is involved in nutrient uptake and neurotransmission in normal physiology. In the context of cancer, this activity is thought to confer a proliferative advantage to tumor cells by making key substrates, such as folate, more readily available for critical processes like DNA synthesis and repair, thereby fueling tumor growth.[2]

Regulation by Androgen Receptor (AR) Signaling

The expression of PSMA is intricately linked to the androgen receptor (AR) signaling pathway, a primary driver of prostate cancer growth. The FOLH1 gene, which encodes PSMA, is generally repressed by androgens.[10] Consequently, androgen deprivation therapy (ADT) or treatment with AR pathway inhibitors (ARPIs) typically leads to an upregulation of PSMA expression on the cell surface.[12] This phenomenon, sometimes referred to as a "PSMA flare," can transiently increase the avidity of PSMA-targeted radiotracers, potentially enhancing the sensitivity of PET imaging.[15]

This regulatory mechanism, however, presents a significant clinical paradox. While short-term ADT may enhance the visibility of tumors on PSMA PET scans, long-term androgen blockade is a key driver of tumor evolution towards castration-resistant and, ultimately, neuroendocrine phenotypes.[18] These aggressive, late-stage forms of prostate cancer are often characterized by the loss of AR signaling and a concomitant loss of PSMA expression, rendering them invisible to PSMA-targeted agents.[18] Thus, the very therapy used to control the disease eventually fosters the emergence of a tumor phenotype that can escape detection and treatment by our most advanced targeted agents. This dynamic underscores the critical need for imaging agents that can visualize tumors irrespective of their AR or PSMA status, providing the central rationale for exploring complementary targets like FAP.

Section 1.2: The Clinical Utility and Limitations of 68Ga-PSMA-11 PET

Gallium-68 (68Ga) PSMA-11, also known as gallium (68Ga) gozetotide, has become the gold standard for prostate cancer PET imaging, profoundly influencing clinical practice due to its high diagnostic accuracy.[21]

Chemical Profile and Mechanism of Action

68Ga-PSMA-11 is a radiopharmaceutical composed of a PSMA-targeting ligand, Glu-Urea-Lys(Ahx), which is conjugated to a chelator, N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid (HBED-CC).[21] This chelator securely binds the positron-emitting radionuclide Gallium-68. Following intravenous administration, the ligand moiety binds with high affinity to the extracellular domain of the PSMA protein on prostate cancer cells. This binding triggers internalization of the PSMA-radiotracer complex, leading to an accumulation of radioactivity within the tumor cells that can be detected by PET imaging.[24]

Diagnostic Performance

Numerous studies and meta-analyses have established the superior diagnostic performance of 68Ga-PSMA-11 PET compared to conventional imaging modalities.

• Initial Staging: For the detection of pelvic lymph node metastases in patients undergoing initial staging, a meta-analysis reported a pooled sensitivity of approximately 0.74 and a specificity of 0.96.[27]
• Biochemical Recurrence (BCR): In patients with suspected recurrence after definitive therapy, 68Ga-PSMA-11 demonstrates a very high positive predictive value (PPV) of around 0.99.[27] Its detection rate is strongly correlated with serum prostate-specific antigen (PSA) levels, with positivity rates of approximately 63% for PSA levels below 2.0 ng/mL and rising to 94% for PSA levels above 2.0 ng/mL.[27]

Impact on Management

The enhanced accuracy of PSMA PET has a direct and significant impact on patient management. The landmark proPSMA trial, a prospective randomized study, found that PSMA PET had an accuracy of 92% for detecting metastatic disease, compared to just 65% for conventional imaging (CT and bone scan).[31] This superior performance led to a change in the planned management for 28% of patients, often by upstaging the disease and thereby avoiding futile local therapies in favor of more appropriate systemic treatments.[34] Its use has also been shown to refine radiotherapy planning by identifying metastatic sites that lie outside of standard treatment fields.[38]

Limitations and False Positives

Despite its success, 68Ga-PSMA-11 has recognized limitations. A primary challenge is the physiologic uptake of the tracer in several normal organs, including the kidneys, salivary glands, spleen, and small intestine, which can obscure or mimic adjacent metastatic lesions.[3] Furthermore, PSMA uptake is not entirely specific to prostate cancer, and false-positive findings are well-documented in a range of benign and malignant conditions, as detailed in Table 1.[42]

Table 1: Common Causes of Physiologic and False-Positive PSMA Uptake

Anatomic Location/Condition	Typical Imaging Appearance	Likelihood of Mimicking Metastasis	Source(s)
Physiologic Uptake
Salivary & Lacrimal Glands	Intense, symmetric uptake	Low (unless asymmetric or focal)	3
Kidneys	Intense, symmetric cortical uptake (renal excretion)	Low	3
Liver & Spleen	Mild to moderate, diffuse uptake	Low	3
Small Bowel (Duodenum/Jejunum)	Mild to moderate, diffuse or linear uptake	Low	3
Sympathetic Ganglia (e.g., Celiac)	Small, symmetric, often para-aortic/celiac foci	Moderate (can mimic small lymph nodes)	48
Benign Pathologies
Bone Fractures (healing)	Focal or linear uptake along fracture lines	Moderate to High	43
Paget's Disease of Bone	Intense uptake in areas of characteristic bone changes on CT	High	43
Fibrous Dysplasia	Variable uptake in areas of ground-glass matrix on CT	High	43
Hemangiomas (vertebral, hepatic)	Focal uptake, often with characteristic CT/MRI findings	Moderate to High	43
Degenerative Joint Disease/Osteophytes	Mild to moderate uptake at articular surfaces	Moderate	44
Inflammatory/Infectious Processes	Variable uptake in areas of inflammation (e.g., sarcoidosis, synovitis)	Moderate to High	46
Malignant Non-Prostate Pathologies
Renal Cell Carcinoma	Often intense uptake in primary tumor or metastases	High	47
Lung Cancer	Variable uptake in primary tumor or metastases	High	47
Thyroid Cancer	Variable uptake in primary tumor or metastases	High	46
Glioblastoma	Variable uptake in brain lesions	High	47

Even with its celebrated accuracy, the "Achilles' heel" of PSMA PET lies in its inability to reliably detect all sites of disease. The proPSMA trial, while demonstrating superiority, still had a false-negative rate of 6%, meaning it missed metastatic disease in a subset of patients.[35] Meta-analyses confirm this, with sensitivity for lymph node detection at approximately 74%, implying that a quarter of metastatic nodes may go undetected.[27] This limitation is particularly pronounced for micrometastatic disease, where tumor deposits are too small to be resolved by PET imaging, and for tumors that exhibit biological heterogeneity, containing clones of cells that do not express PSMA.[50] Therefore, even a "negative" PSMA PET scan cannot definitively rule out the presence of metastatic disease. This fundamental diagnostic gap highlights the need for more sensitive imaging strategies and provides a compelling argument for the development of dual-target tracers like 68Ga-PSFA.

Section 1.3: Next-Generation PSMA-Targeted Radiotracers

The success of 68Ga-PSMA-11 has catalyzed further innovation, primarily focused on overcoming its logistical limitations and improving its diagnostic characteristics.

Fluorine-18 Labeled Tracers

The short 68-minute half-life of Gallium-68, which necessitates on-site production using a 68Ge/68Ga generator, poses logistical and economic challenges for widespread distribution.[51] This has driven the development of tracers labeled with Fluorine-18 (18F), which has a longer half-life of 110 minutes, allowing for centralized cyclotron production and distribution to multiple sites over a wider geographic area.[53]

Comparative Performance

The development of 18F-labeled agents has revealed a critical trade-off between logistical convenience and diagnostic specificity, as shown in Table 2.

• 18F-DCFPyL (Piflufolostat F 18): This agent has demonstrated a diagnostic performance and biodistribution profile largely comparable to 68Ga-PSMA-11. It serves as a suitable alternative with superior logistical properties but does not represent a significant leap in diagnostic capability.[53]
• 18F-PSMA-1007: This tracer was designed to address the issue of urinary excretion seen with 68Ga-PSMA-11 and 18F-DCFPyL. Its predominantly hepatobiliary clearance reduces activity in the bladder, which can improve the visualization of local recurrences and pelvic lymph nodes. However, this benefit is offset by a significant new problem: a high rate of nonspecific uptake in benign bone lesions, which increases the rate of false-positive and equivocal findings and complicates interpretation.[53]

This landscape of next-generation monospecific tracers illustrates that optimizing for one characteristic (e.g., logistics, urinary clearance) can introduce new, unintended drawbacks. There is no single "perfect" PSMA-only agent. This ongoing search for a better tracer underscores the field's acknowledgment of existing limitations and sets the stage for a paradigm shift away from simply refining a single target towards incorporating a second, complementary one, which is the core concept behind 68Ga-PSFA.

Table 2: Comparative Diagnostic Performance of PET Tracers in Prostate Cancer

Radiotracer	Target(s)	Primary Excretion Route	Pooled Sensitivity (Pelvic Nodes)	Pooled Specificity (Pelvic Nodes)	Key Advantages	Key Limitations	Source(s)
68Ga-PSMA-11	PSMA	Renal	~74%	~96%	High specificity; extensive validation.	Short half-life; urinary activity can obscure pelvic lesions.	27
18F-DCFPyL	PSMA	Renal	Similar to 68Ga-PSMA-11	Similar to 68Ga-PSMA-11	Longer half-life allows centralized production.	Urinary activity can obscure pelvic lesions.	53
18F-PSMA-1007	PSMA	Hepatobiliary	High	Lower than other agents	Reduced urinary activity improves pelvic imaging.	High rate of nonspecific benign bone uptake; lower specificity.	53
68Ga-PSFA	PSMA & FAP	Renal/Hepatic (Mixed)	Data Emerging	Data Emerging	Potential for higher overall lesion detection by targeting tumor and stroma.	Potentially lower avidity for single targets; more complex interpretation.	60

II. The Rationale for Dual-Target Imaging: Addressing PSMA Heterogeneity

The limitations of PSMA-only imaging are rooted in the complex biology of prostate cancer, particularly its heterogeneity and mechanisms of treatment resistance. This section details the biological rationale for why a dual-target approach is necessary, introducing Fibroblast Activation Protein (FAP) as the ideal complementary target.

Section 2.1: Mechanisms of Resistance to PSMA-Targeted Therapies

While PSMA-targeted radioligand therapy (RLT), such as 177Lu-PSMA-617, has shown significant survival benefits, resistance is a major clinical challenge.[61] Understanding the mechanisms of this resistance is key to developing more durable therapies.

Tumor Heterogeneity and PSMA Expression Loss

A primary driver of resistance is the inherent heterogeneity of tumors. Most prostate cancers are composed of a mix of PSMA-positive and PSMA-negative cell clones. PSMA-targeted therapy effectively eliminates the PSMA-positive cells, but this creates a selection pressure that allows the pre-existing or newly emerged PSMA-negative clones to proliferate, leading to disease relapse.[19] This is particularly evident in the progression to aggressive, late-stage subtypes like neuroendocrine prostate cancer (NEPC), which is characteristically PSMA-negative and thus inherently resistant to these therapies.[18]

Genomic Drivers of Resistance

The genomic landscape of a tumor can profoundly influence its response to RLT.

• DNA Damage Repair (DDR) Genes: Alterations in DDR genes, such as BRCA2, are associated with increased sensitivity to radiation-induced DNA damage. Paradoxically, this can lead to better initial responses to Lu-PSMA. However, evidence from a rapid autopsy of a BRCA2-mutated patient who progressed on Lu-PSMA showed a profound loss of PSMA expression, suggesting that antigen loss can be a potent escape mechanism even in this genomically "favorable" context.[66]
• Tumor Suppressor Genes and Signaling Pathways: Loss-of-function mutations in key tumor suppressor genes like TP53 and RB1 are associated with radioresistance and the development of the NEPC phenotype.[19] Furthermore, aberrant activation of signaling pathways, most notably the Wnt pathway, is strongly implicated in resistance to both anti-androgen therapy and 177Lu-PSMA-617.[68] Genomic analyses have shown that high expression of FOLH1 (PSMA) is negatively correlated with mutations in Wnt pathway genes such as APC and CTNNB1, suggesting an inverse relationship between PSMA expression and Wnt-driven resistance.[70]

The Tumor Microenvironment (TME)

Resistance is not solely a property of the cancer cell itself but is heavily influenced by the surrounding tumor microenvironment (TME). The TME is often immunosuppressive and can shield cancer cells from therapeutic attack.[71] Different metastatic sites also have unique microenvironments; for instance, liver metastases are associated with a particularly poor response to Lu-PSMA, which may be due to local TME factors.[72] Additionally, a key physical limitation of beta-emitting radionuclides like 177Lu is their "crossfire" effect. While effective for larger tumors, the radiation dose delivered to small tumor cell clusters or micrometastases may be insufficient to be lethal, allowing these microscopic disease sites to survive and seed future relapse.[50]

The multifaceted nature of resistance—spanning tumor cell genetics, the stromal and immune environment, and the physics of radiation delivery—demonstrates that a therapeutic strategy focused on a single cancer cell target is inherently vulnerable to multiple escape pathways. This complex problem demands a more sophisticated solution. An ideal next-generation agent would not only target the cancer cell but also another stable component of the tumor ecosystem, one less susceptible to these resistance pressures. This provides the core scientific justification for targeting FAP, which is expressed on cancer-associated fibroblasts (CAFs) within the tumor stroma.

Section 2.2: Fibroblast Activation Protein (FAP) as a Complementary Target

Fibroblast Activation Protein (FAP) has emerged as a highly promising target for cancer imaging and therapy due to its unique expression pattern and biological role.

FAP Biology and Expression

FAP is a type II transmembrane serine protease that is highly and specifically expressed on the surface of cancer-associated fibroblasts (CAFs).[73] CAFs are a key component of the tumor stroma in a vast array of epithelial cancers, including prostate cancer.[75] In contrast, FAP expression is virtually absent in most healthy adult tissues, making it an excellent target for delivering diagnostic or therapeutic payloads with high tumor-to-background contrast.[73]

FAP-Inhibitor (FAPI) PET Imaging in Prostate Cancer

PET imaging using radiolabeled FAP inhibitors (FAPI) has demonstrated significant potential in prostate cancer, particularly in cases where PSMA imaging falls short. Clinical studies have shown that FAP-avid lesions can be detected in patients with PSMA-negative disease.

• One study reported that 58% of CRPC tumors that were negative for PSMA expression on immunohistochemistry were positive for FAP.[75]
• Another clinical imaging study in a staging cohort found that FAPI-PET was positive in 74% of primary tumors, whereas PSMA-PET was positive in only 52%. Critically, among the PSMA-negative patients in this group, 54% were positive on the FAPI scan, demonstrating the complementary nature of the two targets.[77]

This evidence strongly suggests that the expression of PSMA on cancer cells and FAP on stromal fibroblasts are often complementary. A significant portion of tumors that are "invisible" to PSMA PET can be "seen" with FAPI PET. This establishes the central hypothesis for the development of 68Ga-PSFA: a single, bispecific radiotracer that targets both PSMA and FAP should be able to visualize a more complete and accurate landscape of the total tumor burden, capturing both the epithelial and stromal compartments and thereby overcoming the critical limitation of PSMA-negative disease.[60]

III. Profile of 68Ga-PSFA: A Bispecific PSMA/FAP Radiotracer

68Ga-PSFA represents a novel class of radiopharmaceuticals designed to simultaneously engage two distinct targets within the tumor ecosystem. This section provides a detailed technical and scientific profile of the agent, synthesizing available data on its design, performance, and safety.

Section 3.1: Chemical Structure and Radiolabeling

Molecular Design

68Ga-PSFA is a heterodimeric radiotracer, meaning it is a single molecule engineered to bind to two different targets. Its structure consists of three key components [60]:

1. A PSMA-targeting pharmacophore: Typically a urea-based motif, such as Glu-urea-Lys, which has a high affinity for the enzymatic pocket of the PSMA protein.
2. A FAP-inhibitor (FAPI) pharmacophore: Often a quinoline-based small molecule that binds specifically to the active site of FAP.
3. A chelator: A molecule, such as DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), that is capable of securely binding a metallic radionuclide.

These three components are connected via a chemical linker system. The design of this linker is critical, as its length and chemical properties can influence the binding affinity of each pharmacophore and the overall pharmacokinetic behavior of the final molecule.[73]

Radiolabeling with Gallium-68

The chelator on the PSFA molecule allows it to be radiolabeled with Gallium-68 (68Ga), a positron-emitting radionuclide ideal for PET imaging. 68Ga has a physical half-life of 68 minutes, which is well-suited for the pharmacokinetics of small-molecule tracers. Its production from a Germanium-68/Gallium-68 (68Ge/68Ga) generator allows for on-site, cyclotron-independent radiopharmaceutical preparation, which provides logistical flexibility for clinical sites.[51] However, the generator-based supply can be limited in scale and relatively expensive. To address this, cyclotron-based production methods for 68Ga are being developed as a potential strategy to increase supply and reduce costs, though this requires more significant infrastructure.[51]

Section 3.2: Preclinical and Early Clinical Evaluation

The development of bispecific tracers like 68Ga-PSFA has navigated a critical challenge, revealing a key difference between preclinical models and clinical reality.

Binding Affinity and In Vitro Studies

Preclinical studies of novel bispecific PSMA/FAP tracers, such as Ga-AV01017, have demonstrated that these molecules can retain high, nanomolar binding affinity for both of their intended targets. Reported IC50 values (a measure of inhibitory potency) were in the range of 25–72 nM for PSMA and 1.25–2.74 nM for FAP, confirming dual-target engagement at the molecular level.[73]

A Critical Challenge: Lower Uptake in Monospecific Models

A consistent and important finding from preclinical biodistribution studies is that bispecific tracers exhibit lower tumor uptake in monospecific xenograft models (i.e., tumors expressing only PSMA or only FAP) when compared to their respective monospecific counterparts. For example, the uptake of [68Ga]Ga-AV01017 in PSMA-only tumors was significantly lower than that of a PSMA-only tracer, and its uptake in FAP-only tumors was lower than that of a FAPI-only tracer.[73] This suggests a potential trade-off in binding avidity or pharmacokinetics when two targeting moieties are combined on a single molecule. The length of the chemical linker appears to play a role, with some evidence suggesting that longer linkers can lead to prolonged blood retention and consequently lower tumor accumulation.[73]

The Promise: Superior Detection in Heterogeneous Tumors

Despite the observations in simplified preclinical models, the first-in-human feasibility data for a bispecific tracer, [68Ga]Ga-PSFA-01, has validated the core hypothesis of the dual-targeting strategy. In a direct comparison, [68Ga]Ga-PSFA-01 successfully detected a greater number of metastatic lesions in prostate cancer patients than either [68Ga]Ga-PSMA-11 or [68Ga]Ga-FAPI-04 administered alone.[60]

This apparent contradiction between preclinical and clinical findings reveals a crucial concept. While a bispecific tracer may be a "jack of all trades, master of none" when faced with a homogeneous, single-target tumor, its strength lies in its versatility. In the complex reality of human cancer, where tumors are heterogeneous mosaics of PSMA-positive cancer cells, PSMA-negative cancer cells, and FAP-positive stromal cells, the ability of 68Ga-PSFA to bind to either target allows it to paint a more complete and accurate picture of the total disease burden. Its clinical utility will therefore not be defined by achieving the highest possible signal intensity (SUVmax) in a single lesion, but by its superior ability to detect the true extent of disease. This will necessitate a shift in clinical interpretation, moving away from a focus on single-lesion avidity to a more holistic assessment of disease distribution and volume.

Section 3.3: Dosimetry and Radiation Safety Profile

The radiation safety profile of any new radiopharmaceutical is of paramount importance. While specific dosimetry data for 68Ga-PSFA are not yet available, a robust estimate can be derived from the extensive data available for 68Ga-PSMA-11.

Reference Dosimetry (68Ga-PSMA-11)

For 68Ga-PSMA-11, the organs receiving the highest absorbed radiation dose are those with high physiologic expression of PSMA or those involved in the tracer's excretion. As shown in Table 3, these critical organs are the kidneys, lacrimal glands, and salivary glands.[41] The total effective dose to the patient from a standard administrative activity of 259 MBq (7 mCi) is approximately 4.4 mSv, a level considered safe and comparable to other routine diagnostic PET procedures.[84]

Table 3: Comparative Radiation Dosimetry of 68Ga-Labeled Radiotracers

Organ	Absorbed Dose for 68Ga-PSMA-11 (mGy/MBq)	Absorbed Dose for 68Ga-PSFA (mGy/MBq)
Kidneys	0.24 - 0.413	Data Not Available
Lacrimal Glands	0.11 - 0.12	Data Not Available
Salivary Glands	0.089	Data Not Available
Liver	0.053	Data Not Available
Spleen	0.046	Data Not Available
Red Marrow	0.015	Data Not Available
Urinary Bladder Wall	0.057	Data Not Available
Total Body Effective Dose	0.022 mSv/MBq	Data Not Available
Data synthesized from sources.41

Anticipated Dosimetry of 68Ga-PSFA

The dosimetry profile of 68Ga-PSFA is expected to be broadly similar to that of 68Ga-PSMA-11, with contributions from both PSMA and FAP expression patterns. Since FAP is also expressed in the liver and spleen, these organs might exhibit slightly higher absorbed doses with the bispecific agent compared to PSMA-11 alone. However, the overall effective dose is anticipated to remain well within established safety limits for diagnostic imaging. Formal dosimetry studies will be a critical component of upcoming clinical trials to confirm these projections and ensure patient safety.

IV. Clinical and Theranostic Implications of 68Ga-PSFA

The development of 68Ga-PSFA is not merely an incremental improvement in imaging technology; it has the potential to fundamentally alter clinical practice and pave the way for a new generation of cancer therapies.

Section 4.1: Potential Impact on Clinical Management

Improved Staging and Patient Selection

The most immediate impact of 68Ga-PSFA will likely be in disease staging. By providing a more accurate map of the total tumor burden, including lesions that are PSMA-negative, the tracer could lead to significant changes in patient management.[60] Accurately distinguishing between localized disease, oligometastatic disease (a limited number of metastases), and widespread metastatic disease is a critical decision point that determines whether a patient is a candidate for curative-intent local therapy (like surgery or radiation) or requires systemic therapy.[36] A more precise staging tool could prevent the under-treatment of patients with occult metastatic disease and spare patients with widespread disease from the toxicities of futile local treatments.

Enhanced Radiotherapy (RT) Planning

Effective radiotherapy depends on the precise delineation of all tumor sites. PSMA PET has already been shown to significantly impact RT planning by identifying metastases located outside of conventional treatment fields, leading to modifications in up to 50% of cases.[36] By detecting additional FAP-positive/PSMA-negative lesions, 68Ga-PSFA could further refine RT target volumes. This would allow for more comprehensive treatment of all disease sites, potentially improving the efficacy of salvage radiotherapy and metastasis-directed therapy (MDT) while better sparing adjacent healthy tissues.

Monitoring Therapy Response

The expression of both PSMA and FAP can change dynamically in response to treatment. For example, ADT can alter PSMA expression, and other therapies may affect the tumor stroma and FAP expression.[14] A bispecific tracer that can monitor both the cancer cells and their microenvironment could provide a more robust and comprehensive tool for assessing treatment response, capturing the emergence of resistant clones that may have altered their target expression profiles.

Section 4.2: The Future of Bispecific Theranostics

The ultimate promise of 68Ga-PSFA extends beyond diagnostics. It serves as the pioneering scout for a new class of therapeutics: bispecific radioligand therapy.

Diagnostic Precursor to Bispecific RLT

The development of 68Ga-PSFA is the first half of a theranostic pair. The logical next step is the creation of a therapeutic analogue, such as 177Lu-PSFA or 225Ac-PSFA, where the diagnostic 68Ga is replaced with a therapeutic radionuclide. This pairing would allow clinicians to first use 68Ga-PSFA PET to identify patients with either PSMA- or FAP-positive disease and then treat them with a single therapeutic agent capable of delivering cytotoxic radiation to both the cancer cells and their supportive stromal fibroblasts.[60]

Overcoming Resistance to Monospecific RLT

This bispecific therapeutic strategy directly addresses the key resistance mechanism of antigen loss. A tumor that escapes treatment with 177Lu-PSMA by downregulating PSMA expression could still be effectively targeted by 177Lu-PSFA via its FAP-expressing stroma.[19] This represents a fundamental shift from a "targeted" therapy, which focuses on a single protein on a single cell type, to an "ecosystem" therapy. It acknowledges that a tumor is a complex biological system and that durable control requires disrupting not only the cancer cells but also the supportive environment that enables them to thrive.

Potential for Combination Therapies

The radiation delivered by RLT can modulate the tumor microenvironment, creating opportunities for synergistic combinations. A bispecific RLT like 177Lu-PSFA could be paired with immunotherapy to overcome the TME's immunosuppressive barriers or with PARP inhibitors in patients with DDR gene mutations to achieve synergistic DNA damage and enhanced cell killing.[89]

Section 4.3: Standardization and Interpretation Challenges

The clinical implementation of a novel, dual-target imaging agent presents unique challenges for standardization and interpretation.

• Adapting Reporting Frameworks: Current standardized reporting systems, such as PSMA-RADS (Prostate-Specific Membrane Antigen Reporting and Data System) for lesion-level confidence and PROMISE (Prostate Cancer Molecular Imaging Standardized Evaluation) for miTNM staging, were designed exclusively for PSMA-targeted imaging.[93] Interpreting a bispecific scan will be inherently more complex. Consensus guidelines will be needed to address questions such as how to classify a lesion that is PSMA-negative but FAP-positive, or how to integrate information from two different targets into a single, clinically actionable report.
• Quantitative Imaging and Artificial Intelligence (AI): The complexity of dual-tracer data makes it an ideal domain for the application of AI and radiomics. Machine learning models could be trained to automatically segment PSMA-positive and FAP-positive tumor volumes, calculate quantitative parameters (e.g., PSMA-Total Volume, FAP-Total Volume, Total Lesion PSMA/FAP), and correlate these complex imaging signatures with clinical outcomes.[8] Such tools will be essential for extracting the full prognostic and predictive value from these rich datasets and translating them into clinical practice.

V. Recommendations and Future Directions

The successful translation of 68Ga-PSFA from a promising concept to a standard-of-care clinical tool will require a strategic development path that addresses key scientific, logistical, and economic hurdles.

Section 5.1: Recommendations for Clinical Development

• Pivotal Trial Design: The most critical next step is a prospective, multicenter, head-to-head clinical trial comparing 68Ga-PSFA PET/CT to the current standard, 68Ga-PSMA-11 PET/CT. The primary endpoint should be the per-patient detection rate of metastatic disease, with a composite reference standard that includes histopathology and long-term clinical and imaging follow-up.
• Key Patient Populations for Study: To maximize the potential impact, trials should prioritize patient populations where the limitations of PSMA-only imaging are most pronounced:
• Patients with biochemical recurrence at very low PSA levels (<0.5 ng/mL), where the sensitivity of PSMA-11 is known to be limited.
• Patients with mCRPC who are progressing on long-term ADT and are at high risk of developing PSMA-negative or neuroendocrine disease.
• Patients being considered for PSMA-targeted RLT who have equivocal or low-avidity disease on a baseline PSMA-11 scan.

Section 5.2: Overcoming Barriers to Adoption

• Manufacturing and Logistics: While the use of 68Ga generators provides convenience for on-site preparation, scaling up production to meet widespread clinical demand will be a significant challenge. The limited daily yield of generators may necessitate a parallel development strategy, such as exploring cyclotron production of 68Ga or creating an 18F-labeled version of PSFA (e.g., 18F-PSFA) to leverage the more robust distribution network available for fluorine-based radiopharmaceuticals.[51]
• Cost-Effectiveness and Reimbursement: The path to broad clinical adoption is ultimately paved with health economics. The proPSMA trial serves as a critical blueprint, having demonstrated not only the superior accuracy of PSMA PET but also its potential cost-effectiveness by helping to avoid futile treatments and guide more appropriate therapy.[110] The reimbursement landscape in both the United States and Europe is complex and fragmented, even for established therapies.[112] A new, and likely more expensive, bispecific agent like 68Ga-PSFA will face intense scrutiny from payers. Therefore, it is imperative that the clinical development program for 68Ga-PSFA includes prospective health economic analyses from its earliest stages. Data demonstrating that more accurate staging leads to improved long-term patient outcomes and downstream cost savings will be as crucial as the clinical efficacy data for securing favorable reimbursement policies and ensuring patient access.[115]

Section 5.3: Concluding Remarks on the Potential of 68Ga-PSFA

68Ga-PSFA stands as a highly promising, next-generation radiopharmaceutical that represents a logical and scientifically driven evolution in molecular imaging. By moving beyond a single target on the cancer cell, it embraces a more holistic, ecosystem-based approach to visualizing prostate cancer, targeting both the malignant cell via PSMA and its supportive stromal environment via FAP. While significant challenges remain in optimizing its molecular design, validating its clinical performance, standardizing its interpretation, and navigating the path to reimbursement, its potential is clear. 68Ga-PSFA has the capacity to more accurately stage disease, guide therapy with greater precision, and, most importantly, unlock the door to a new era of bispecific theranostics. Its continued development places it at the forefront of innovation in nuclear medicine and the personalized management of prostate cancer.

Works cited

1. Glutamate carboxypeptidase II - Wikipedia, accessed June 18, 2025, https://en.wikipedia.org/wiki/Glutamate_carboxypeptidase_II
2. FOLH1 Gene - GeneCards | FOLH1 Protein | FOLH1 Antibody, accessed June 18, 2025, https://www.genecards.org/cgi-bin/carddisp.pl?gene=FOLH1
3. Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment - MDPI, accessed June 18, 2025, https://www.mdpi.com/2072-6694/16/24/4263
4. Novel Role of Prostate-Specific Membrane Antigen in Suppressing Prostate Cancer Invasiveness - AACR Journals, accessed June 18, 2025, https://aacrjournals.org/cancerres/article/65/3/727/518762/Novel-Role-of-Prostate-Specific-Membrane-Antigen
5. Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis - Frontiers, accessed June 18, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00623/full
6. Prostate-Specific Membrane Antigen Biology and Pathophysiology in Prostate Carcinoma, an Update: Potential Implications for Targeted Imaging and Therapy - MDPI, accessed June 18, 2025, https://www.mdpi.com/1422-0067/25/17/9755
7. pmc.ncbi.nlm.nih.gov, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9365343/#:~:text=PSMA%20is%20generally%20highly%20expressed,cancer%20(9%E2%80%9312).
8. Whole-body tumor burden semi-automatic evaluation on ⁶⁸Ga-PSMA PET/CT... | Download Scientific Diagram - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/figure/Whole-body-tumor-burden-semi-automatic-evaluation-on-Ga-PSMA-PET-CT-of-a-61-year-old_fig1_344321622
9. Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9365343/
10. Relationship between androgen receptor (AR) activity and PSMA... - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/figure/Relationship-between-androgen-receptor-AR-activity-and-PSMA-expression-Several-reports_fig1_336819118
11. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen | PNAS, accessed June 18, 2025, https://www.pnas.org/doi/10.1073/pnas.1106383108
12. Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8835452/
13. 68 Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience - Journal of Nuclear Medicine, accessed June 18, 2025, https://jnm.snmjournals.org/content/58/1/81
14. Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [18F]DCFPyL PET Imaging - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9910584/
15. Impact of Three-Month Androgen Deprivation Therapy on [68Ga]Ga-PSMA-11 PET/CT Indices in Men with Advanced Prostate Cancer—Results from a Pilot Prospective Study - MDPI, accessed June 18, 2025, https://www.mdpi.com/2072-6694/14/5/1329
16. Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET | Journal of Nuclear Medicine, accessed June 18, 2025, https://jnm.snmjournals.org/content/early/2025/02/06/jnumed.124.268340/tab-figures-data
17. Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/349581240_Flare_phenomenon_in_prostate_cancer_recent_evidence_on_new_drugs_and_next_generation_imaging
18. Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells | PNAS, accessed June 18, 2025, https://www.pnas.org/doi/10.1073/pnas.2025710119
19. ASCO GU 2022: Mechanisms of Resistance to Radiopharmaceuticals - UroToday, accessed June 18, 2025, https://www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-prostate-cancer/135413-asco-gu-2022-mechanisms-of-resistance-to-radiopharmaceuticals.html
20. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells - Spandidos Publications, accessed June 18, 2025, https://www.spandidos-publications.com/10.3892/ijo.2012.1649
21. Gallium Ga-68 gozetotide | C44H59GaN6O17 | CID 154572876 - PubChem, accessed June 18, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/154572876
22. Gallium (68Ga) gozetotide - Wikipedia, accessed June 18, 2025, https://en.wikipedia.org/wiki/Gallium_(68Ga)_gozetotide
23. [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8401928/
24. Ga 68 PSMA-11: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed June 18, 2025, https://go.drugbank.com/drugs/DB16019
25. Healthcare Professional (HCP) Site for Illuccix®(kit for the preparation of gallium Ga 68 gozetotide Injection), accessed June 18, 2025, https://illuccixhcp.com/
26. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ILLUCCIXTM Powder for Solution, 25 microgram PSMA-11 per vial Kit for, accessed June 18, 2025, https://pdf.hres.ca/dpd_pm/00067755.PDF
27. Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6581235/
28. 68Ga-PSMA-11 PET and mpMRI in the diagnosis of initial lymph node staging of prostate cancer: a head-to-head comparative meta-analysis - Frontiers, accessed June 18, 2025, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1425134/full
29. The Current Landscape of PSMA PET Imaging in Prostate Cancer: Evaluating Men with Biochemical Recurrence - UroToday, accessed June 18, 2025, https://www.urotoday.com/library-resources/imaging-center/139875-the-current-landscape-of-psma-pet-imaging-in-prostate-cancer-evaluating-men-with-biochemical-recurrence.html
30. Diagnostic performance of 68Ga-PSMA PET/CT for restaging prostate cancer, accessed June 18, 2025, https://jnm.snmjournals.org/content/60/supplement_1/1568
31. APCCC Diagnostics 2025: How Do You Translate Next-Generation Imaging to Conventional Imaging for Treatment Decisions? - UroToday, accessed June 18, 2025, https://www.urotoday.com/conference-highlights/apccc-diagnostics-2025/158684-apccc-diagnostics-2025-how-do-you-translate-next-generation-imaging-to-conventional-imaging-for-treatment-decisions.html
32. ProPSMA: A Callout to the Nuclear Medicine Community to Change Practices with Prospective, High-Quality Data, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7198385/
33. EAU 2020: ProPSMA Study: A Prospective Randomised Multi-Centre Study of PSMA-PET/CT Imaging for Staging High Risk Prostate Cancer Prior to Curative-Intent Surgery or Radiotherapy - UroToday, accessed June 18, 2025, https://www.urotoday.com/conference-highlights/eau-2020/prostate-cancer/123157-eau-2020-propsma-study-a-prospective-randomised-multi-centre-study-of-psma-pet-ct-imaging-for-staging-high-risk-prostate-cancer-prior-to-curative-intent-surgery-or-radiotherapy.html
34. Editorial ProPSMA: a callout to the nuclear medicine community to change practice with prospective, high-quality data Michael S. Hofman1,2, accessed June 18, 2025, https://jnm.snmjournals.org/content/jnumed/early/2020/04/03/jnumed.120.245647.full.pdf
35. The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer | EurekAlert!, accessed June 18, 2025, https://www.eurekalert.org/news-releases/613733
36. The role of PET-PSMA in guiding prostate cancer radiation therapy: experience in a salvage and curative setting - SciELO Colombia, accessed June 18, 2025, http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S2027-01192023000200036
37. The IMPACT of [68]GA-PSMA-PET in definitive radiotherapy planning for prostate cancer patients. - ASCO, accessed June 18, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT178943
38. Impact of PSMA-PET/CT on Radiotherapy Decisions: Is There a Clinical Benefit? - MDPI, accessed June 18, 2025, https://www.mdpi.com/2072-6694/17/8/1350
39. The Impact of PSMA PET/CT Imaging in Prostate Cancer Radiation Treatment - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8960055/
40. Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence—A Narrative Review of the Literature | Journal of Nuclear Medicine, accessed June 18, 2025, https://jnm.snmjournals.org/content/60/10/1394
41. Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6328430/
42. APCCC Diagnostics 2025: False Positive PSMA PET: What to Know? - UroToday, accessed June 18, 2025, https://www.urotoday.com/conference-highlights/apccc-diagnostics-2025/158672-apccc-diagnostics-2025-false-positive-psma-pet-what-to-know.html
43. Factors Predicting Metastatic Disease in 68 Ga-PSMA-11 PET–Positive Osseous Lesions in Prostate Cancer - Journal of Nuclear Medicine, accessed June 18, 2025, https://jnm.snmjournals.org/content/61/12/1779
44. Case report: positive pitfalls of PSMA PET/CT: diagnostic challenges in degenerative bone lesions including MODIC type 1 - Frontiers, accessed June 18, 2025, https://www.frontiersin.org/journals/nuclear-medicine/articles/10.3389/fnume.2024.1451848/full
45. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings, accessed June 18, 2025, https://www.periodicos.capes.gov.br/index.php/acervo/buscador.html?task=detalhes&source=all&id=W3011546611
46. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings - PMC - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7071711/
47. Benign and Malignant Non-prostatic Processes Depicted by PSMA PET/CT, accessed June 18, 2025, https://jnm.snmjournals.org/content/65/supplement_2/241496
48. Gallium-68–Labeled Prostate-Specific Membrane Antigen–11 PET/CT of Prostate and Nonprostate Cancers | AJR - American Journal of Roentgenology, accessed June 18, 2025, https://ajronline.org/doi/10.2214/AJR.19.21084
49. PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality? - MDPI, accessed June 18, 2025, https://www.mdpi.com/2077-0383/12/22/7130
50. ASCO 2025: Radioligand Therapy Remix: Finding the Right Patient for the Perfect Track, accessed June 18, 2025, https://www.urotoday.com/conference-highlights/asco-2025/asco-2025-prostate-cancer/160987-asco-2025-radioligand-therapy-remix-finding-the-right-patient-for-the-perfect-track.html
51. Production of cyclotron-based Gallium-68 radioisotope and related radiopharmaceuticals | IAEA, accessed June 18, 2025, https://www.iaea.org/projects/crp/f22073
52. Cyclotron Production of Gallium-68 Radiopharmaceuticals Using the 68Zn(p,n)68Ga Reaction and Their Regulatory Aspects - MDPI, accessed June 18, 2025, https://www.mdpi.com/1999-4923/15/1/70
53. Comparison of 18F-Based PSMA Radiotracers with [68Ga]Ga-PSMA-11 in PET/CT Imaging of Prostate Cancer-a Systematic Review and Meta-Analysis - Beyond the Abstract - UroToday, accessed June 18, 2025, https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/149002-comparison-of-18f-based-psma-radiotracers-with-68ga-ga-psma-11-in-pet-ct-imaging-of-prostate-cancer-a-systematic-review-and-meta-analysis-beyond-the-abstract.html
54. New PET Imaging Tracers for the Primary Staging of Unfavorable Intermediate and High-Risk Prostate Cancer - UroToday, accessed June 18, 2025, https://www.urotoday.com/library-resources/imaging-center/157319-new-pet-imaging-tracers-for-the-primary-staging-of-unfavorable-intermediate-and-high-risk-prostate-cancer.html
55. Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/38017295/
56. Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11238039/
57. Study compares 18F-based PSMA radiotracers to [68Ga]Ga-PSMA-11 - Urology Times, accessed June 18, 2025, https://www.urologytimes.com/view/study-compares-18f-based-psma-radiotracers-to-68ga-ga-psma-11
58. Comparison of [¹⁸F]PSMA-1007, [¹⁸F]DCFPyL, and [⁶⁸Ga]Ga-PSMA-11 in PET/CT Imaging for Prostate Cancer: A Systematic Review and Meta-Analysis | Journal of Nuclear Medicine, accessed June 18, 2025, https://jnm.snmjournals.org/content/66/supplement_1/251575
59. Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6954457/
60. Identification and stability of [¹⁸F]AlF-PSMA-FAPI-01 (A) and... - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/figure/Identification-and-stability-of-FAlF-PSMA-FAPI-01-A-and-FAlF-PSMA-FAPI-02-B_fig2_359394205
61. Efficacy and Toxicity of [ 177 Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data - Journal of Nuclear Medicine, accessed June 18, 2025, https://jnm.snmjournals.org/content/65/11/1740
62. Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/39327018/
63. Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study, accessed June 18, 2025, https://www.novartis.com/us-en/news/media-releases/novartis-177lu-psma-617-significantly-improves-overall-survival-and-radiographic-progression-free-survival-men-metastatic-castration-resistant-prostate-cancer-phase-iii-vision-study
64. Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond, accessed June 18, 2025, https://ascopubs.org/doi/pdf/10.1200/EDBK_350946
65. Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10262652/
66. Genomic correlates of PSMA expression and response to 177Lu-PSMA-617: A Retrospective multi-center cohort study - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11275557/
67. PSMA expression and response to 177Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations. - ASCO Publications, accessed June 18, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5055
68. ASCO 2025: Plasma Epigenomic Profiling to Reveal Molecular Correlates of Response and Resistance to 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer - UroToday, accessed June 18, 2025, https://www.urotoday.com/conference-highlights/asco-2025/asco-2025-prostate-cancer/160933-asco-2025-plasma-epigenomic-profiling-to-reveal-molecular-correlates-of-response-and-resistance-to-177lu-psma-617-in-metastatic-castration-resistant-prostate-cancer.html
69. Wnt Signaling and Therapeutic Resistance in Castration-Resistant Prostate Cancer - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10664806/
70. Molecular and clinical correlates of high PSMA/FOLH1 mRNA expression in primary and metastatic prostate cancer (PC). - ASCO Publications, accessed June 18, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5051
71. PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12055665/
72. Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond | American Society of Clinical Oncology Educational Book - ASCO Publications, accessed June 18, 2025, https://ascopubs.org/doi/10.1200/EDBK_350946
73. Synthesis and Preclinical Evaluation of Three Novel Ga-Labeled Bispecific PSMA/FAP-Targeting Tracers for Prostate Cancer Imaging - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/367343843_Synthesis_and_Preclinical_Evaluation_of_Three_Novel_68Ga-Labeled_Bispecific_PSMAFAP-Targeting_Tracers_for_Prostate_Cancer_Imaging
74. Synthesis and Preclinical Evaluation of Three Novel 68Ga-Labeled Bispecific PSMA/FAP-Targeting Tracers for Prostate Cancer Imaging - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/36770755/
75. FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. - UroToday, accessed June 18, 2025, https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/155953-fap-and-psma-expression-by-immunohistochemistry-and-pet-imaging-in-castration-resistant-prostate-cancer-a-translational-pilot-study.html
76. FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. - FirstWord Pharma, accessed June 18, 2025, https://firstwordpharma.com/story/5908291
77. Contribution of 68 Ga-DOTA-FAPI-04 PET/CT to Prostate Cancer Imaging : Complementary Role in PSMA-Negative Cases - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/38271254/
78. Synthesis and Preclinical Evaluation of Three Novel 68 Ga-Labeled Bispecific PSMA/FAP-Targeting Tracers for Prostate Cancer Imaging - MDPI, accessed June 18, 2025, https://www.mdpi.com/1420-3049/28/3/1088
79. Processing of Generator-Produced 68 Ga for Medical Application - Journal of Nuclear Medicine, accessed June 18, 2025, https://jnm.snmjournals.org/content/48/10/1741
80. Radionuclide generators: the prospect of availing PET radiotracers to meet current clinical needs and future research demands, accessed June 18, 2025, https://e-century.us/files/ajnmmi/9/1/ajnmmi0086228.pdf
81. Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9803810/
82. (PDF) Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients, accessed June 18, 2025, https://www.researchgate.net/publication/330323116_Radiation_dosimetry_of_68GaPSMA-11_in_low-risk_prostate_cancer_patients
83. Estimation of Radiation Dosimetry for 68Ga-HBED-CC (PSMA-11) in Patients with Suspected Recurrence of Prostate Cancer, accessed June 18, 2025, https://scholarworks.indianapolis.iu.edu/bitstream/1805/14344/1/Green_2016_estimation.pdf
84. Gallium Ga 68 PSMA-11 Injection, for intravenous use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed June 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf
85. Radiation dosimetry of [Ga-68]PSMA-11 in low-risk prostate cancer patients - DiVA portal, accessed June 18, 2025, http://www.diva-portal.org/smash/record.jsf?pid=diva2:1283194
86. Impact of PSMA PET on Prostate Cancer Management - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11034977/
87. Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer | RadioGraphics - RSNA Journals, accessed June 18, 2025, https://pubs.rsna.org/doi/abs/10.1148/rg.2020200058
88. Precision Medicine: The Future of ARPI-PARP Combos and PSMA PET Imaging, accessed June 18, 2025, https://www.guoncologynow.com/post/precision-medicine-the-future-of-arpi-parp-combos-and-psma-pet-imaging
89. PSMA and Beyond 2025: Keynote Lecture: Improving Outcomes with Combination Therapy, accessed June 18, 2025, https://www.urotoday.com/conference-highlights/2025-ucsf-ucla-psma-conference/159350-psma-and-beyond-2025-keynote-lecture-improving-outcomes-with-combination-therapy.html
90. LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). - ASCO, accessed June 18, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT413834
91. PARP Inhibitor Therapy for Prostate Cancer Patients: Emerging Combinations - UroToday, accessed June 18, 2025, https://www.urotoday.com/library-resources/advanced-prostate-cancer/150515-parp-inhibitor-therapy-for-prostate-cancer-patients-emerging-combinations.html
92. Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11083597/
93. Prostatic Specific Membrane Antigen Reporting and Data System (PSMA-RADS) Version 1.0 - ClinicalTrials.gov, accessed June 18, 2025, https://cdn.clinicaltrials.gov/large-docs/17/NCT06359717/Prot_SAP_000.pdf
94. PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6859641/
95. (PDF) Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/373393986_Reliability_and_practicability_of_PSMA-RADS_10_for_structured_reporting_of_PSMA-PETCT_scans_in_prostate_cancer_patients
96. PROMISE Standardized Reporting of PSMA-PET in Prostate Cancer, accessed June 18, 2025, https://promise-pet.org/
97. Inter-Observer Variability in the Interpretation of 68Ga-PSMA PET-CT Scan according to PROMISE Criteria - Scientific Research Publishing, accessed June 18, 2025, https://www.scirp.org/journal/paperinformation?paperid=117475
98. Reading and Reporting a PSMA PET Scan for Staging Prostate Cancer - Andrea Farolfi, accessed June 18, 2025, https://www.urotoday.com/video-lectures/psma-academy/video-2/2411-reading-and-reporting-a-psma-pet-scan-for-staging-prostate-cancer-andrea-farolfi.html
99. Prognostic value of quantitative PSMA-PET parameters during chemotherapy in prostate cancer. | Journal of Clinical Oncology - ASCO Publications, accessed June 18, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.33
100. ASCO GU 2025: Prognostic Value of Quantitative PSMA-PET Parameters During Chemotherapy in Prostate Cancer - UroToday, accessed June 18, 2025, https://www.urotoday.com/conference-highlights/asco-gu-2025/asco-gu-2025-prostate-cancer/158135-asco-gu-2025-prognostic-value-of-quantitative-psma-pet-parameters-during-chemotherapy-in-prostate-cancer.html?utm_source=newsletter_13875&utm_medium=email&utm_campaign=asco-gu-2025-prostate-cancer-day-1-highlights-treatment-imaging-biomarkers&acm=_13875
101. Quantitative PSMA-PET prostate cancer: Advancing in clinical trials - Quibim, accessed June 18, 2025, https://quibim.com/news/from-images-to-insights-quantitative-psma-pet-coupled-with-ai-in-prostate-cancer-clinical-trialspsma/
102. Study Examines Prognostic Value of Baseline PSMA PET/CT Factors in Patients with mCRPC - Diagnostic Imaging, accessed June 18, 2025, https://www.diagnosticimaging.com/view/study-prognostic-value-baseline-psma-pet-ct-factors-patients-with-mcrpc
103. Initial Experience with Volumetric 68 Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer - Journal of Nuclear Medicine, accessed June 18, 2025, https://jnm.snmjournals.org/content/58/12/1962
104. The Role of Radiomics and Artificial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/40429314/
105. The Role of Radiomics and Artificial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12112297/
106. (PDF) The Role of Radiomics and Artificial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/391620365_The_Role_of_Radiomics_and_Artificial_Intelligence_Applied_to_Staging_PSMA_PET_in_Assessing_Prostate_Cancer_Aggressiveness
107. Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens - MDPI, accessed June 18, 2025, https://www.mdpi.com/2075-4418/14/2/181
108. PSMA PET/CT radiomics: Assessment of Adverse Pathological Risk and Proteomic Biomarker Correlations in Prostate Cancer | Journal of Nuclear Medicine, accessed June 18, 2025, https://jnm.snmjournals.org/content/65/supplement_2/241486
109. Multicentric 68Ga-PSMA PET radiomics for treatment response assessment of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer - Frontiers, accessed June 18, 2025, https://www.frontiersin.org/journals/nuclear-medicine/articles/10.3389/fnume.2023.1234853/full
110. The Cost-Effectiveness of PSMA-PET/CT When Compared with Conventional Imaging, An Analysis Informed by the proPSMA Trial - Journal Club - Christopher Wallis & Zachary Klaassen - UroToday, accessed June 18, 2025, https://www.urotoday.com/video-lectures/journal-club/video/2245-the-cost-effectiveness-of-psma-pet-ct-when-compared-with-conventional-imaging-an-analysis-informed-by-the-propsma-trial-journal-club-christopher-wallis-zachary-klaassen.html
111. The “ProPSMA Study” clinical trial protocol: A prospective randomized multi-center study of the impact of Ga-68 PSMA PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy. - ASCO Publications, accessed June 18, 2025, https://ascopubs.org/doi/10.1200/JCO.2019.37.7_suppl.TPS138
112. Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020 - PubMed Central, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10199877/
113. Full article: Costs of radium-223 and the pharmacy preparation 177Lu-PSMA-I&T for metastatic castration-resistant prostate cancer in Dutch hospitals - Taylor & Francis Online: Peer-reviewed Journals, accessed June 18, 2025, https://www.tandfonline.com/doi/full/10.1080/13696998.2023.2183618
114. Radioligand therapy for advanced prostate cancer patients – We need to boost our health care systems | Knowledge for policy, accessed June 18, 2025, https://knowledge4policy.ec.europa.eu/projects-activities/radioligand-therapy-advanced-prostate-cancer-patients-%E2%80%93-we-need-boost-our_en
115. Cost-effectiveness of the implementation of [68Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging - PubMed, accessed June 18, 2025, https://pubmed.ncbi.nlm.nih.gov/35962838/
116. Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery | Journal of Nuclear Medicine, accessed June 18, 2025, https://jnm.snmjournals.org/content/60/10/1359
117. Cost-effectiveness of the implementation of [68Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging - PMC, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9375809/
118. Cost-effectiveness of the implementation of [68Ga]Ga-PSMA PET/CT at initial staging of prostate cancer patients | Journal of Nuclear Medicine, accessed June 18, 2025, https://jnm.snmjournals.org/content/63/supplement_2/3047
119. (PDF) Cost-effectiveness of the implementation of [68Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging - ResearchGate, accessed June 18, 2025, https://www.researchgate.net/publication/362679789_Cost-effectiveness_of_the_implementation_of_68GaGa-PSMA-11_PETCT_at_initial_prostate_cancer_staging
120. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial, accessed June 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10547650/
121. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial | springermedizin.de, accessed June 18, 2025, https://www.springermedizin.de/is-psma-pet-ct-cost-effective-for-the-primary-staging-in-prostat/25598530